Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Edwards Lifesciences Corp (NYSE:EW), the $42 billion medical devices company currently trading at $71.62, Chief Financial Officer Scott B. Ullem reported significant stock transactions on February 28, 2025, according to a recent SEC filing. Based on InvestingPro analysis, the company’s stock is currently trading near its Fair Value with strong financial health metrics. Ullem exercised options to acquire 11,250 shares of common stock at a price of $45.28 per share, amounting to a total value of approximately $509,362.
On the same day, Ullem sold a total of 11,250 shares in two separate transactions. The first sale involved 3,490 shares at an average price of $71.38, while the second sale consisted of 7,760 shares at an average price of $70.52. The total value of these sales reached approximately $796,326. These transactions were executed under a Rule 10b5-1 trading plan adopted by Ullem in August 2024.
Following these transactions, Ullem holds 30,387 shares directly and 266,318 shares indirectly, by trust. For deeper insights into Edwards Lifesciences’ insider transactions and comprehensive financial analysis, including 8 additional ProTips, access the full research report on InvestingPro.
In other recent news, Edwards Lifesciences reported strong financial results for the fourth quarter of 2024, with revenues reaching $1.39 billion, surpassing the anticipated $1.36 billion. The company’s adjusted earnings per share (EPS) also exceeded expectations, coming in at $0.59 compared to the forecasted $0.55. The Transcatheter Aortic Valve Replacement (TAVR) segment generated $1.04 billion in revenue, marking a 5.3% year-over-year increase. The Transcatheter Mitral and Tricuspid Therapies (TMTT) division showed impressive growth with an 85% increase in sales, contributing $105.1 million. Canaccord Genuity raised its price target for Edwards Lifesciences to $71, maintaining a Hold rating, while Stifel reiterated a Buy rating with a $90 target, reflecting confidence in the company’s growth trajectory. Edwards Lifesciences reiterated its 2025 guidance, expecting total sales between $5.6 billion and $6.0 billion, with TAVR and TMTT sales projected to grow significantly. The company continues to focus on expanding its global presence and maintaining strong R&D investments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.